Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 14/20 | 0.80 |
| ▸ | ADORA3 | P0DMS8 | 11/20 | 0.80 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.80 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.80 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.73 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.58 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6745873 | 1.00 | ADORA1 (0.80) | ADORA1ADORA3ADORA2AADORA2BCYP2D6 | |
| SCHEMBL6745863 | 1.00 | ADORA1 (0.80) | ADORA1ADORA3ADORA2AADORA2BCYP2D6 | |
| SCHEMBL6745849 | 1.00 | ADORA1 (0.80) | ADORA1ADORA3ADORA2AADORA2BCYP2D6 | |
| SCHEMBL6745843 | 1.00 | ADORA1 (0.80) | ADORA1ADORA3ADORA2AADORA2BCYP2D6 | |
| Trabodenoson SCHEMBL14829316 | 0.89 | ADORA1 (1.00) | ADORA1ADORA3ADORA2AADORA2BTAS1R3 | |
| Trabodenoson SCHEMBL29359454 | 0.89 | ADORA1 (1.00) | ADORA1ADORA3ADORA2AADORA2BTAS1R3 | |
| Trabodenoson SCHEMBL15183438 | 0.89 | ADORA1 (1.00) | ADORA1ADORA3ADORA2AADORA2BTAS1R3 | |
| Trabodenoson SCHEMBL121828 | 0.89 | ADORA1 (1.00) | ADORA1ADORA3ADORA2AADORA2BTAS1R3 | |
| Trabodenoson SCHEMBL17513019 | 0.89 | ADORA1 (1.00) | ADORA1ADORA3ADORA2AADORA2BTAS1R3 | |
| SCHEMBL124574 | 0.88 | ADORA1 (1.00) | ADORA1ADORA3ADORA2AADORA2BTAS1R3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183224-B2 | Purine derivatives as adenosine A1 receptor agonists and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2012-05-22 | — | — | US | disclosed |
| US-20090062314-A1 | Purine derivatives as adenosine A1 receptor agonists and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2009-03-05 | — | — | US | disclosed |
| US-7423144-B2 | Purine Derivatives as adenosine A1 receptor agonists and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2008-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062314-A1 | Purine derivatives as adenosine A1 receptor agonists and methods of use thereof | ADORA2A, ADORA1, ADORA3 | ADORA1 2/4885ADORA3 3/4885ADORA2A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.